IBRX Stock ImmunityBio (IBRX, $2.49) Stochastic Oscillator left the oversold zone on April 29, 2025

GET DAILY SIGNALS

Get AI intraday signals

IBRX - ImmunityBio

Stochastic signal

View

Odds of UP Trend

Price: $2.49

Daily change: -$0.14 (-5.32%)

Daily volume: 4.4M

Industry: Biotechnology

IBRX in -11.15% downward trend, sliding for three consecutive days on April 17, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IBRX declined for three days, in of 348 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on April 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

IBRX moved below its 50-day moving average on March 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for IBRX entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on May 01, 2025. You may want to consider a long position or call options on IBRX as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.935). P/E Ratio (0.000) is within average values for comparable stocks, (64.473). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.881). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (120.482) is also within normal values, averaging (254.313).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.